Skin Side Effects U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
|
|
- Ashley Beasley
- 5 years ago
- Views:
Transcription
1 Skin Side Effects Christiane Thallinger, M D U N I V E R S I T Y OF V I E N N A, D E P A R T M E N T OF O N C O L O G Y, G E N E R A L H O S P I T A L V I E N N A
2 Targets Substances 1 Multi Kinase Inhibitors Sorafinib Sunitinib Pazopanib... mtor Inhibitors Everolimus.... Morais et al, Journal of Kidney Cancer and VHL 2014
3 Targets Substances 2 Multi Kinase Inhibitors Sorafinib Sunitinib Pazopanib... mtor Inhibitors Everolimus.... Morais et al, Journal of Kidney Cancer and VHL 2014
4 Substances and Side Effects 3 EGFR-I MK-I BRAF-I MEK-I c-kit mtor maculapapular eruption (+) (+) ++ (+) acneiform rash ++ (+) (Sorafenib) HFSR alopecia + (+) (Sorafenib) paronychia hair changes trichomegaly, hypertrichoses, pigment changes hypopigmentation (Sunitinib) - - pigment changes - xerosis/pruritus + + (+) ++ + (+) skin tumors - + Sorafenib Degen et al, HAUTARZT 2011
5 Substances and Side Effects 4 EGFR-I MK-I BRAF-I MEK-I c-kit mtor maculapapular eruption (+) (+) ++ (+) acneiform rash ++ (+) (Sorafenib) HFSR alopecia + (+) (Sorafenib) paronychia hair changes trichomegaly, hypertrichoses, pigment changes hypopigmentation (Sunitinib) - - pigment changes - xerosis/pruritus + + (+) ++ + (+) skin tumors - + Sorafenib Degen et al, HAUTARZT 2011
6 Targets Substances 5 MK Inhibition Sorafinib Sunitinib Pazopanib... TKIs approved for treatment of of several malignancies TKIs treatment can be limited by poor tolerability TKI induced side effects include rash, alopecia, depigmentation, pruritus, xerosis, rash, and mucositis Most troublesome - hand-foot skin reaction different from hand-foot syndrome of cytotoxic chemotherapeutic
7 MKI induced HFSR Hand-Foot Skin Reaction (HFSR) 6 Diffuse painful oedema and redness of palms and sols Hyperkeratotic plaques develop predominantly over sites of pressure (heels, metatarsal heads, areas of friction caused by manual work) Lesions are sharply demarcated, erythematous, oedematous, painful Very tender blisters evolve into inflamed skin Distinct from the HFS (palmar-plantar erythrodysesthesia) associated with 5FU and capecitabine indicates different therapy strategies!
8 MKI induced HFSR 7 Common Terminology Criteria for Adverse Events Version 4.0 Grade 1 Minimal skin changes OR dermatitis (erythema, oedema, or hyperkeratosis without pain) Grade 2 Skin changes (peeling, blisters, oedema, or hyperkeratosis) with pain, slightly limiting instrumental ADL Grad 3 Severe skin changes (peeling, blisters, bleeding, oedema, or hyperkeratosis) with pain limiting self-care ADL
9 MKI induced HFSR 8 Hand-Foot Skin Reaction (HFSR) Grade 2 Grade 1 Grade 3
10 HFSR Facts Incidence of 1% to 45% in patients treated with multikinase inhibitors Include epidermal keratinocyte apoptosis, dyskeratosis and vacuolar degeneration with intraepidermal blister Initial symptoms of HFSR typically appear within the first 2 6 weeks of treatment. 9 Several weeks after initial symptoms, thickened or hyperkeratotic skin may appear, which may be painful and impair range of motion, and function, and weight bearing Gomez et al, The Oncologist 2011 Segaert et al, Eur J Cancer 2009
11 HFSR Pathogenesis 10 The remaining mechanisms are poorly understood HSFR does not appear to be related to increased excretion of the agent through sweat VEGF is not synthesized by keratinocytes or eccrine glands Alterations in keratinocytes by inhibition of c-kit may be hypothesized to cause HFSR - however the incidence of HFSR associated with Imatinib treatment is low! Possible VEGF inhibition in the vascular endothelium may be involved in HFSR (blocking VEGF via MKI increases tumor vessel regression via inhibition of endothelial cell survival) Meadows et al, Support Care Cancer 2015 Lai et al, J Clin Oncol 2007 Lee et al, BJD 2009
12 HFSR Pathogenesis 11 Limited dermatopathologic studies reported inflammatory and vascular changes changes consistent with wound healing Keratinocytes synthesize PDGF-α and PDGF-β, which bind PDGFRs on dermal fibroblasts, capillaries, and eccrine glands (Dermal eccrine glands express c-kit and PDGFR) Co-inhibition of VEGFR and PDGFR decrease vessels to repair Many endothelial functions vasodilatation, proliferation and survival are mediated by nitric oxide (NO) NO is downregulated by anti-vegf therapy Meadows et al, Support Care Cancer 2015 Lai et al, J Clin Oncol 2007 Erber et al, FASEB 2014
13 HFSR Treatment 12.moisturising creams, urea 20% cream, topical corticosteroid (clobetasol 0.05% cream)..modifying daily activities, reduce friction and heat exposure.dose reduction or dose interruption of the MK-inhibitor New approach: Sidenafil topically (1% sidenafil cream) Sidenafil approved by the FDA for the treatment of erectile dysfunction and pulmonary hypertension Sidenafil has been shown to improve wound healing Pilot study by Meadows et al mitigated HFSR symptoms
14 Substances and Side Effects 13 EGFR-I MK-I BRAF-I MEK-I c-kit mtor maculapapular eruption (+) (+) ++ (+) acneiform rash ++ (+) (Sorafenib) HFSR alopecia + (+) (Sorafenib) paronychia hair changes trichomegaly, hypertrichoses, pigment changes hypopigmentation (Sunitinib) - - pigment changes - xerosis/pruritus + + (+) ++ + (+) skin tumors - + Sorafenib Degen et al, HAUTARZT 2011
15 MKI induced RASH 14 Maculopapular rash is characterized by a flat, red area on the skin that is covered with small confluent papules, and also includes erythema
16 MKI induced RASH Common Terminology Criteria for Adverse Events Version 4.0 Grade 1 15 Macules/papules covering <10% BSA with OR without symptoms (e.g., pruritus, burning, tightness) Grade 2 Macules/papules covering 10-30% BSA with OR without symptoms (e.g., pruritus, burning, tightness); limiting instrumental activities of daily living (ADL). Grad 3 Macules/papules covering >30% BSA with OR without associated symptoms; limiting self-care ADL, majority of the cases associated with local superinfection (oral antibiotics indicated)
17 MKI induced RASH 16 Rash affects the upper trunk, spreading centripetally, associated with pruritus Rash is seen in 19% to 53% patients treated with multikinase inhibitors occurs early in therapy (within the first cycle of therapy) disappear without treatment in less than 2 months Pickert et al, J Drugs Dermatol 2011 Macdonald et al, J Am Acad Dermatol, 2015
18 RASH - Treatment 17 maculopapular rash is associated with skin inflammation that leads to pruritus oral antihistamine such as loratadine during the day and a sedative antihistamine such as hydroxyzine mg at night Menthol creams for pruritus relief (Menthol cream 0.5-3%) Oral antiepileptic (gabapentin etc.) should be used only in exceptional cases of very resistant itch as second-or third-line treatment topical corticosteroid (e.g. clobetasol 0.05%) Macdonald et al, J Am Acad Dermatol, 2015
19 Skin Toxicity and Quality of Life 18 Cutaneous toxicities affect patient function and quality of life, which may lead to dose modification or discontinuation Toxicity grading correlated with health-related quality of life Cutaneous adverse effects are among the most frequently encountered, and significantly impact both quality of life and health care economics Nardone et al, J Drugs Dermatol 2012 Lee at al, BJD 2009 Macdonald et al, J Am Acad Dermatol, 2015
20 Economic Burden of SAEs (I) 19 Median cost by category of treatment as it relates to targeted drug. Borovicka et al, ARCH DERMATOL 2011
21 Economic Burden of SAEs (II) 20 Borovicka et al, ARCH DERMATOL 2011
Multikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven
More informationCutaneous reactions to targeted therapies. Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017
Cutaneous reactions to targeted therapies Stavonnie Patterson, MD, FAAD Northwestern University Feinberg School of Medicine March 6, 2017 Disclosures I have no relevant disclosures Papulopustular Eruption
More informationManaging common toxicities with new tyrosine kinase inhibitors
Managing common toxicities with new tyrosine kinase inhibitors TKIs are involved in treating an increasing number of cancer indications. Doctors need to be aware of the range of potentially serious side
More informationPei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科
Pei-han Kao, 高珮菡 Department of Dermatology, Chang Gang Memorial Hospital 林口長庚醫院皮膚科 Clear evidence that rash presence/severity correlates with response May compromise quality of life and require to minimize
More informationIdentifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy. An educational resource for healthcare professionals
Identifying and managing dermatologic toxicities associated with EGFR-inhibitor therapy An educational resource for healthcare professionals What to expect from EGFR-inhibitor therapy The goal of EGFR-inhibitor
More informationDermatologists & Oncologists: Two important reasons we are getting closer. Ioanna Panoutsopoulou, MD. GAMC June 1 st 2016
Dermatologists & Oncologists: Two important reasons we are getting closer Ioanna Panoutsopoulou, MD GAMC June 1 st 2016 Points of presentation Cutaneous adverse events from: Epidermal Growth Factor Receptor
More information17/01/2017. ckit NRAS BRAF MEK ERK. ANTITUMOR IMMUNE RESPONSE PROLIFERATION
BRAF inhibitors: vemurafenib (Zelboraf ) dabrafenib (Tafinlar ) Universitair Ziekenhuis Gent MEK inhibitors: cobimetinib trametinib(mekinist ) selumetinib CUTANEOUS SIDE EFFECTS OF BRAF-INHIBITORS Lieve
More informationUpdates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash. Outline. Signal Transduction
Updates in the Management of Epidermal Growth Factor Receptor (EGFR) Inhibitors- Induced Skin Rash Siu-Fun Wong, PharmD, FASHP, FCSHP Associate Professor of Pharmacy Practice Western University of Health
More informationImaging Cancer Treatment Complications in the Chest
Imaging Cancer Treatment Complications in the Chest Michelle S. Ginsberg, MD Objectives Imaging Cancer Treatment Complications in the Chest To understand the mechanisms of action of different classes of
More informationAcute drug reactions associated with the novel targeted therapies used in treating skin cancer
Acute drug reactions associated with the novel targeted therapies used in treating skin cancer Dr Rishika Sinha Consultant Dermatologist Chelsea & Westminster Hospital NHS Foundation Trust West Middlesex
More informationTargeted Therapies 5/21/2018. Iatrogenic Dermatopathology: When Therapy Goes Wrong
Iatrogenic Dermatopathology: When Therapy Goes Wrong Tammie Ferringer, MD Geisinger Medical Center, Danville, PA tferringer@geisinger.edu I do not have any relevant relationships with industry Targeted
More informationSide effects of Targeted Therapy
Side effects of Targeted Therapy Joanne Bird NIHR Research Fellow Clare Warnock Senior Project Nurse Types of Anti Cancer Therapy Biological Therapies Cytotoxic Drugs (Chemotherapy) Antibiotics Antimetabolites
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationBRAF Inhibition in Melanoma
BRAF Inhibition in Melanoma New York City, Mar 22-23, 2013 Bartosz Chmielowski, MD, PhD Assistant Clinical Professor University of California Los Angeles Disclosures Speaker Bureau: BMS, Genentech, Prometheus
More informationPrimary Care Management of the Kidney Cancer Patient
Primary Care Management of the Kidney Cancer Patient Elaine Lam, MD Mountain States Cancer Conference 2016 November 5, 2016 Learning Objectives 1. Understand the mechanisms of action of currently approved
More informationEGFR inhibitors. EGFR inhibitors. Cutaneous side effects of EGFRinhibitors. EGFR inhibitor skin toxicity. EGFR is abundantly expressed in the skin
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of EGFRinhibitors and their management Siegfried Segaert Dermatology Dept University Hospital Leuven Belgium
More informationcontinuing education Prevention and management of hand-foot syndromes Jia Conway, DNP, FNP-BC, NP-C
continuing education educational objectives After participating in this activity, clinicians should be better able to Identify a novel anticancer therapy that contributes to hand-foot syndromes and hand-foot
More informationMEK/BRAF inhibitors and the implications on patients and health care providers
MEK/BRAF inhibitors and the implications on patients and health care providers Tara McKeown NP Paediatric Neuro Oncology Hospital for Sick Children Adjunct Lecturer, Lawrence S. Bloomberg, Faculty of Nursing,
More informationNewsletter of Hong Kong Society of Palliative Medicine
Palliative Medicine Grand Round in the era of targeted biological therapies: What is new and what does one need to know? Dr. Roland Leung, Specialist in Medical Oncology, Clinical Research Associate, Department
More informationStudy No Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationIntegumentary System-Skin and Body Coverings
Integumentary System-Skin and Body Coverings List the four types of epithelial or connective membranes. The epithelial cutaneous includes your and is exposed to the. Its function is to. An example is..
More informationHONG KONG COLLEGE OF MEDICAL NURSING 香港內科護理學院. Wong Sin Ting. RN, BScN, MScHC, PgDHSM, FHKAN (Medical Oncology) HKGALI T13_49_45
HONG KONG COLLEGE OF MEDICAL NURSING 香港內科護理學院 Wong Sin Ting RN, BScN, MScHC, PgDHSM, FHKAN (Medical Oncology) HKGALI2014 09 02T13_49_45 Disclosure No honorarium is received for the nurse lecture Non Surgical
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SUNitinib 50mg Therapy INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of unresectable and/or metastatic malignant gastrointestinal C26 00325a CDS stromal tumour (GIST)
More informationNursing s Role in the Management of New Oral Chemotherapy Agents
Nursing s Role in the Management of New Oral Chemotherapy Agents Mechelle Barrick BSN, RN, OCN, CCRP Clinical Research Nurse Coordinator Greater Baltimore Medical Center mbarrick@gbmc.org THE NURSES ROLE
More informationProspective Case Series of Cutaneous Adverse Effects Associated With Dabrafenib and Trametinib
670368CMSXXX10.1177/1203475416670368Journal of Cutaneous Medicine and SurgeryLacroix and Wang research-article2016 Original Article Prospective Case Series of Cutaneous Adverse Effects Associated With
More informationEczema. By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University
Eczema By:- Dr. Naif Al-Shahrani Salman bin Abdazziz University Dermatitis= Eczema =Spongiosis Eczema Atopic Seborrheic Contact Allergic Irritant Nummular Asteatotic Stasis Neurodermatitis/Lichen Simplex
More informationCheckpoint inhibitors: Strategies to checkmate T-cell mediated toxicity. Disclosure Statement. Learning Objectives
Checkpoint inhibitors: Strategies to checkmate T-cell mediated toxicity Adam J. DiPippo, PharmD Clinical Pharmacy Specialist Leukemia Texas Society of Health-System Pharmacists 2017 Annual Seminar April
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationLung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Afatinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA310 First line treatment option in locally advanced or metastatic NSCLC Positive test for epidermal growth factor receptor
More informationColorectal Cancer Therapy and Associated Toxicity
Colorectal Cancer Therapy and Associated Toxicity Mountain States Cancer Conference November 6, 2010 Colin D. Weekes, M.D., Ph.D Assistant Professor University of Colorado GI Cancers Are Common 2009 Estimated
More information4. Pityriasis lichenoides
Go Back to the Top To Order, Visit the Purchasing Page for Details usually more than 5 cm in diameter and accompanied by poikiloderma. Some but not all patients may develop mycosis fungoides (Fig. 22.35).
More informationGrover s disease: A case report.
320 Case report Thai J Dermatol, October-December 2011 ABSTRACT: Grover s disease: A case report. Supicha Chavanich MD, Praneet Sajjachareonpong MD. CHAVANICH C, SAJJACHAREONPONG P. GROVER S DISEASE: A
More informationPrinciples of Anatomy and Physiology
Principles of Anatomy and Physiology 14 th Edition CHAPTER 5 The Integumentary System Introduction The organs of the integumentary system include the skin and its accessory structures including hair, nails,
More informationAn Update on EGFR Inhibitors. Disclosure. Objectives 4/1/2011. Leigh M. Boehmer, Pharm.D., has no real or apparent conflicts of interest to report
An Update on EGFR Inhibitors Leigh M. Boehmer, Pharm.D., BCOP Clinical Pharmacist, Medical Oncology Barnes Jewish Hospital Saint Louis, Missouri Disclosure Leigh M. Boehmer, Pharm.D., has no real or apparent
More informationCTCAE & Source Documentation. Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research
CTCAE & Source Documentation Elizabeth Ness, RN, MS Director, Office of Education and Compliance Center for Cancer Research Agenda 1.Definition of AE 2.AE standards 3.AE documentation 4.AE and data quality
More informationNew Oncology Drugs: Nadeem Ikhlaque, M.D Subtitle Would Go Here
New Oncology Drugs: A PowerPoint Brief Primer Cover Title Nadeem Ikhlaque, M.D 05.19.2017 Subtitle Would Go Here Learning Objectives List novel chemotherapies and the indications of these newer agents
More informationCutaneous Adverse Drug Reactions in Domestic Animals. Katherine Doerr, DVM, Dip. ACVD. Veterinary Dermatology Center
Cutaneous Adverse Drug Reactions in Domestic Animals Katherine Doerr, DVM, Dip. ACVD Veterinary Dermatology Center Maitland, Rockledge, Waterford Lakes, FL Not highly studied in veterinary medicine Unknown
More informationLiposomal Doxorubicin (CAELYX) Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment
More informationEczema & Dermatitis Clinical features: Histopathological features: Classification:
Eczema & Dermatitis Eczema is an inflammatory reactive pattern of skin to many and different stimuli characterized by itching, redness, scaling and clustered papulovesicles. Eczema and dermatitis are synonymous
More informationCurrent Status of Studies on Targeted Therapy for Renal Cell Carcinoma
294 Chin J Clin Oncol (2008) 5: 294~298 DOI 10.1007/s11805-008-0294-x Current Status of Studies on Targeted Therapy for Renal Cell Carcinoma Shaoqi Wang 1 Shaoxiang Wang 2 Juan Wang 1 1 Department of Oncology,
More informationIntegumentary System
Integumentary System Integumentary System Skin, hair, and nails. Skin: Epidermis: outer layer. Dermis: also called corium, or true skin. Subcutaneous fascia: innermost layer. Integumentary Glands Sudoriferous:
More informationCitation The Journal of Dermatology, 37(8), available at
NAOSITE: Nagasaki University's Ac Title Two cases of blaschkitis with promi Author(s) Utani, Atsushi Citation The Journal of Dermatology, 37(8), Issue Date 2010-08 URL Right http://hdl.handle.net/10069/25634
More information0BCore Safety Profile. Pharmaceutical form(s)/strength: Cream 1% DK/H/PSUR/0009/005 Date of FAR:
0BCore Safety Profile Active substance: Pimecrolimus Pharmaceutical form(s)/strength: Cream 1% P-RMS: DK/H/PSUR/0009/005 Date of FAR: 06.06.2013 4.3 Contraindications Hypersensitivity to pimecrolimus,
More informationMechanisms and Management of Diarrhoea from Anti-VEGFR-TKIs. Manuela Schmidinger Medical University of Vienna Austria
Mechanisms and Management of Diarrhoea from Anti-VEGFR-TKIs Manuela Schmidinger Medical University of Vienna Austria Clinical Presentation Frequency and severity varies between patients Intensity is dose-dependent
More informationModern therapy in oncology Metastatic melanoma
Modern therapy in oncology Metastatic melanoma Anna Buda-Nowak Oncology Department; University Hospital in Cracow Melanoma Malignant skin neoplasm derived from neuroectodermal melanomatous cells. The incidence:
More informationSafety Considerations and Side Effect Management with Tyverb (Lapatinib)
Safety Considerations and Side Effect Management with Tyverb (Lapatinib) Prescribing information can be found at the end of the presentation Date of prep: 19-Sep-2011 UK/LPD/0226a/11 HER2 (ErbB2)-positive
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationWhat You Need to Know about Advanced Melanoma Therapies Targeted Approaches
2018 AAD Annual Meeting, San Diego, CA What You Need to Know about Advanced Melanoma Therapies Targeted Approaches Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion & Melanoma
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationChapter 6 Skin and the Integumentary System. Skin Cells. Layers of Skin. Epidermis Dermis Subcutaneous layer beneath dermis not part of skin
Chapter 6 Skin and the Integumentary System Composed of several tissues Maintains homeostasis Protective covering Retards water loss Regulates body temperature Houses sensory receptors Contains immune
More informationSkin lesions & Abrasions
Skin lesions & Abrasions What Are Skin Lesions? A skin lesion is a part of the skin that has an abnormal growth or appearance compared to the skin around it Types of Skin Lesions Two types of skin lesions
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationSUNitinib 37.5mg Therapy
INDICATIONS FOR USE: SUNitinib 37.5mg Therapy Regimen Code INDICATION ICD10 Treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationIntegumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition)
Integumentary System (Skin) Unit 6.3 (6 th Edition) Chapter 7.3 (7 th Edition) 1 Learning Objectives Identify the major components (anatomy) of skin Differentiate between the two types of skin glands Explain
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationAcademia Pharma Intersect: Symptom Management. Memorial Sloan-Kettering Cancer Center, New York, New York, USA
The Oncologist Academia Pharma Intersect: Symptom Management and Supportive Care Clinical Presentation and Management of Hand Foot Skin Reaction Associated with Sorafenib in Combination with Cytotoxic
More informationManaging Adverse Events in the Cancer Patient. Learning Objectives. Chemotherapy-Induced Nausea/Vomiting
Managing Adverse Events in the Cancer Patient Lisa A Thompson, PharmD, BCOP Assistant Professor University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Learning Objectives Describe
More informationA Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive Patients
Journal of US-China Medical Science 12 (2015) 85-89 doi: 10.17265/1548-6648/2015.02.008 D DAVID PUBLISHING A Retrospective Study of Spectrum of Nevirapine Induced Cutaneous Drug Reactions in HIV Positive
More informationPhotosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel
Vol. 23, Suppl. 3, 2011 http://dx.doi.org/10.5021/ad.2011.23.s3.s314 CASE REPORT Photosensitivity Reactions to Vandetanib: Redevelopment after Sequential Treatment with Docetaxel Young-Min Son, M.D., Joo-Young
More informationProfilo di tossicita degli inibitori di EGFR
Dipartimento di Oncologia direttore dr. Gianpiero Fasola NSCLC EGFR mutato: quali opzioni terapeutiche? Profilo di tossicita degli inibitori di EGFR Padova 17 settembre 2105 Alessandro Follador TKis in
More informationManagement of side-effects of anti-angiogenetic inhibitors in treating HCC
Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli dimaiomax@libero.it BCLC staging system and treatment strategy
More informationSkin toxicities from cancer treatments
Outline Skin toxicities from cancer treatments Resident Power Hour Cecilia Larocca, MD Centers for Melanoma and Cutaneous Oncology Brigham and Women s Hospital/Dana- Farber Cancer Institute Harvard Medical
More informationBCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Trametinib
BCCA Protocol Summary for the Treatment of BRAF V600 Mutation- Positive Unresectable or Metastatic Melanoma Using dabrafenib and Protocol Code Tumour Group Contact Physician USMAVDT Skin and Melanoma Dr.
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationPrincipi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile Grand rounds. Lorenzo Cerroni, Graz
Principi ed Aggiornamenti in Dermatologia Roma, 6-7 Aprile 2018 Grand rounds Lorenzo Cerroni, Graz "Computer palms" Described in patient using computer keyboards for long periods; similar features described
More informationAngiogenesis Targeted Therapies in Renal Cell Carcinoma
Angiogenesis Targeted Therapies in Renal Cell Carcinoma John S. Lam, MD Department of Urology David Geffen School of Medicine University of California-Los Angeles Patient Case CC: Abdominal pain VS: T
More informationIntegumentary System and Body Membranes
Integumentary System and Body Membranes The Skin and its appendages hair, nails, and skin glands Anatomy/Physiology NHS http://www.lab.anhb.uwa.edu.au/mb140/corepages/integumentary/integum.htm I. System
More informationIntegumentary System
Integumentary System Physiology of Touch Skin: our most sensitive organ Touch: first sense to develop in embryos Most important but most neglected sense How many sensory receptors do we have? (We have
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationDue next week in lab - Scientific America Article Select one article to read and complete article summary
Due in Lab 1. Skeletal System 33-34 2. Skeletal System 26 3. PreLab 6 Due next week in lab - Scientific America Article Select one article to read and complete article summary Cell Defenses and the Sunshine
More informationDegos Disease: A Case Report and Review of Literature
Degos Disease: A Case Report and Review of Literature Monira waked Egyptian Dermatology Online Journal 4 (1): 5, June 2008 Al Houd Al Marsod Hospital Submitted for publication: May 25 th, 2008 Accepted
More informationSecond - Line Debate: Axitinib
Second - Line Debate: Axitinib Alain Ravaud, MD PhD Bordeaux, France DISCLOSURES Member of Global, European and/or French advisory board in RCC and/or GU tumors for Pfizer, Novartis, GSK, Roche, BMS, Merck.
More informationADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE
Tivozanib Hydrochloride in Advanced Renal Cell Carcinoma ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE AVEO PHARMACEUTICALS, INC. 75 Sidney Street Cambridge, MA 02139 Tel: (617) 299-5000
More informationRameshwar Gutte and Uday Khopkar
Extragenital unilateral lichen sclerosus et atrophicus in a child: a case report Rameshwar Gutte and Uday Khopkar Department of Dermatolgy, Seth GSMC and KEM Hospital, Parel, Mumbai-400012, India Egyptian
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationBIOH111. o Cell Module o Tissue Module o Integumentary system o Skeletal system o Muscle system o Nervous system o Endocrine system
BIOH111 o Cell Module o Tissue Module o Integumentary system o Skeletal system o Muscle system o Nervous system o Endocrine system Endeavour College of Natural Health endeavour.edu.au 1 Textbook and required/recommended
More informationSkin Deep Into Toxicities of Cancer Therapies. Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY
Skin Deep Into Toxicities of Cancer Therapies Mario E Lacouture MD Member, Memorial Hospital Director, Oncodermatology Program New York, NY Targeting the Immune System in Cancer. Sharma et al, Nat Rev
More informationPsoriasis Case presentation 2 Ahmad is 50 years old male came to the on call dermatologist with a 3 day history of feeling generally unwell and
Psoriasis Case presentation 2 Ahmad is 50 years old male came to the on call dermatologist with a 3 day history of feeling generally unwell and redness of all skin associated with de-sequamation scaling.
More informationIntroduction. Skin and Body Membranes. Cutaneous Membranes Skin 9/14/2017. Classification of Body Membranes. Classification of Body Membranes
Introduction Skin and Body Membranes Body membranes Cover surfaces Line body cavities Form protective and lubricating sheets around organs Classified in 5 categories Epithelial membranes 3 types- cutaneous,
More informationA. Erythema multiforme and related diseases
Go Back to the Top To Order, Visit the Purchasing Page for Details Chapter Erythema, Erythroderma (Exfoliative Dermatitis) Erythema is caused by telangiectasia or hyperemia in the papillary and reticular
More informationSkin and Body Membranes
4 Skin and Body Membranes PowerPoint Lecture Slide Presentation by Jerry L. Cook, Sam Houston University ESSENTIALS OF HUMAN ANATOMY & PHYSIOLOGY EIGHTH EDITION ELAINE N. MARIEB Skin and Body Membranes
More informationCHAPTER 7:3 INTEGUMENTARY SYSTEM
CHAPTER 7:3 INTEGUMENTARY SYSTEM I. OBJECTIVES A. Label a diagram of a cross section of the skin B. Differentiate between the two types of skin glands C. Identify six functions of the skin D. Provide the
More informationWhat Are the Different Forms?
SCARRING/CICATRICIAL ALOPECIA Scarring alopecia also known as cicatricial alopecia, refers to a collection of hair loss disorders that may be diagnosed in up to 3% of hair loss patients. It occurs worldwide
More informationChapter 6: Integumentary System
Shier, Butler, and Lewis: Hole s Human Anatomy and Physiology, 12 th ed. Chapter 6: Skin and the Integumentary System Chapter 6: Integumentary System I. Introduction 1. The skin is composed of of tissues.
More informationRadioiodine-refractory DTC
Oncology: Radioiodine-refractory DTC New Developments in Giuseppe COSTANTE, MD, Head, Endocrinology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Targeted Therapies Targeted Treatments
More informationHospital-based Dermatopathology. Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM
Hospital-based Dermatopathology Janis M. Taube, MD Director of Dermatopathology Johns Hopkins University SOM Overview Drug-eruptions Erythroderma Manifestations of renal disease Blistering disorders Vasculitis/Vasculopathy
More informationNintedanib in Oncology Backgrounder
For media outside the US, UK and Canada only Nintedanib in Oncology Backgrounder 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. Additional clinical data 5. Nintedanib approval
More informationINTEGUMENTARY SYSTEM PART I: FUNCTIONS & EPIDERMIS
INTEGUMENTARY SYSTEM PART I: FUNCTIONS & EPIDERMIS Integumentary System Cutaneous membrane Epidermis (5-layers) made up of epithelial tissue only Dermis (2-layers) contains connective tissue, vessels,
More informationCutaneous Conditions Associated with Systemic Disease
Cutaneous Conditions Associated with Systemic Disease Johnnie M Woodson, M.D., F.A.A.D. Assistant Professor of Dermatology University of Nevada School of Medicine Director of J. Woodson Dermatology & Associates,
More informationHole s Human Anatomy and Physiology. Eleventh Edition. Chapter 6
Hole s Human Anatomy and Physiology Eleventh Edition Shier Butler Lewis Chapter 6 Copyright The McGraw-Hill Companies, Inc. Permission required for reproduction or display. 1 Referred to as Cutaneous Membrane
More informationPRODUCT MONOGRAPH. Trametinib Tablets. 0.5 mg and 2 mg. ATC Code: L01XE23 Protein Kinase Inhibitor
PRODUCT MONOGRAPH Pr MEKINIST Trametinib Tablets 0.5 mg and 2 mg ATC Code: L01XE23 Protein Kinase Inhibitor Novartis Pharmaceuticals Canada Inc. Date of Revision: 385 Bouchard Blvd. September 21, 2018
More informationCHAPTER 5 INTEGUMENTARY
CHAPTER 5 INTEGUMENTARY skin under the skin other stuff cutaneous layer hypodermis (subcutaneous) accessory structures Cutaneous layer = skin epithelial layers = connective tissue layer = dermis Subcutaneous
More informationLung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Indication: NICE TA258 NICE TA162 Locally advanced or metastatic NSCLC as a first line treatment option Positive test for epidermal growth
More informationEarly View Article: Online published version of an accepted article before publication in the final form.
: Online published version of an accepted article before publication in the final form. Journal Name: International Journal of Case Reports and Images (IJCRI) Type of Article: Case Report Title: A Case
More information